CG Oncology's Cretostimogene: Durable Response in High-Risk Bladder Cancer
Cretostimogene, a new bladder cancer treatment, shows durable 24-month complete responses (41.8%) in high-risk patients unresponsive to BCG. It has a good safety profile and offers bladder-sparing potential, with approval submission planned.